Daily Stock List
Xenetic Biosciences, Inc. (XBIO)
TopPennyStockMovers, The MicrocapNews, and Real Pennies reported earlier on Xenetic Biosciences, Inc. (XBIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Xenetic Biosciences, Inc. is a biopharmaceutical company centering on developing next-generation biologic drugs and novel oncology therapeutics. Its proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs. Xenetic Biosciences’ platforms also include OncoHist™ for the development of novel oncology drugs centered on orphan indications. Xenetic Biosciences is based in Lexington, Massachusetts.
Xenetic’s lead product candidates include ErepoXen®. This is a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Additionally, its lead product candidates include OncoHist™. This is a novel recombinant human histone H1.3 molecule for the treatment of refractory Acute Myeloid Leukemia (AML) with the potential to treat many other cancer indications.
Xenetic Biosciences is working together with Russia-based OJSC Pharmsynthez and the Serum Institute of India to test additional drug and vaccine candidates and to de-risk the development process with clinical data generated in Russia and India before the Company takes these candidates into the clinic in Western markets. OJSC Pharmsynthez is an affiliate of a major shareholder in Xenetic Biosciences.
Regarding PolyXen®, it is an enabling platform technology for protein drug delivery. PolyXen® uses the natural polymer polysialic acid (PSA) to prolong the drug's half-life and potentially improve the stability of therapeutic peptides and proteins.
In September 2015, Xenetic Biosciences announced that its contracts and arrangements with Baxter Healthcare SA and Baxter Healthcare Corp. (together referred to as Baxter) (BAX) were assigned to Baxalta, Inc. (BXLT) as part of the spin out of the company’s biopharmaceutical business. Xenetic Biosciences has an exclusive research, development, license and supply agreement with Baxalta to develop products with an extended half-life of certain proteins and molecules employing Xenetic’s patent protected PolyXen® technology.
Xenetic Biosciences has commenced the third cohort of its Phase 2 dose-escalation study with its lead drug candidate ErepoXen® for the treatment of anemia in pre-dialysis chronic kidney disease patients.
Recently, Xenetic Biosciences announced that it entered into an Asset Purchase Agreement (APA) with AS Kevelt, an Estonian biotech company (Kevelt) and OJSC Pharmsynthez (Pharmsynthez, and together with Kevelt, Sellers). With this APA, the Sellers will transfer to Xenetic Biosciences certain intellectual property (IP) rights regarding Virexxa™, and Xenetic will receive the worldwide rights to develop, market and license Virexxa for all uses, except for certain excluded uses within the Commonwealth of Independent States (the CIS), in exchange for 111.5 million shares of Xenetic Biosciences’ common stock and certain other consideration.
Virexxa is a Phase II oncology drug candidate. It is under investigation for the treatment of certain endometrial cancers. As part of this total consideration, Xenetic Biosciences will also acquire Kevelt's U.S. Orphan Drug designation for the use of Virexxa in the treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.
Xenetic Biosciences, Inc. (XBIO), closed Friday's trading session at $0.25, up 4.17%, on 9,975 volume with 4 trades. The average volume for the last 60 days is 28,393 and the stock's 52-week low/high is $0.18/$1.14.
Baristas Coffee Company, Inc. (BCCI)
PennyStocks24, PennyStockRumors.net, PricelessPennyStocks, SmallCapVoice, SuperNova Elite, and Top Stock Picks reported earlier on Baristas Coffee Company, Inc. (BCCI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Baristas Coffee Company, Inc. formed to create a national brand of drive-thru espresso stands. The Company is accomplishing this through acquiring established businesses that fit its model, opening new locations, and by franchising. Baristas Coffee Company is the largest and fastest growing costume-themed drive through Espresso Company in the country. Baristas Coffee Company is based in Seattle, Washington.
The Company can be found in greater Seattle area locations, and also in Florida, and Montana. It has company owned locations and has commenced franchising. Furthermore, it has also started opening locations in shopping malls. Baristas Coffee Company has its theme of joining attractive female baristas in entertaining costumes preparing premium beverages. Baristas provides its customers hot and cold beverages, specializing in specialty coffees, blended teas, and other custom drinks.
The Company also offers smoothies, fresh-baked pastries, and other confections. In season, it adds beverages including hot apple cider, hot chocolate, frozen coffees, and more. Another revenue stream for Baristas is in promoting and selling Baristas™ merchandise; alluring calendars, mugs, t-shirts, and hats.
Baristas Coffee Company announced in May of 2015 that it entered into a joint venture (JV) agreement with BMOC Partners to expand operations of the Mall Café format of Baristas Coffee Company throughout the State of New York. The JV will be owned 51 percent by Baristas and 49 percent by BMOC. BMOC is a regional hospitality and Franchise operations enterprise. BMOC’s founders have broad experience in creating, marketing, and running multiple franchise systems.
The JV will be managed primarily by BMOC under the Baristas Café concept. The locations that are in malls in Pennsylvania are Baristas franchises owned and operated by BMOC Partners. Baristas Coffee Company will recognize revenue consistent with other majority owned JV’s in Florida.
Last week, Baristas Coffee Company announced that it was approved to export to Mexico the only White Coffee single serve cups compatible with the Keurig® K-Cup® Brewing System 2.0 available anywhere in Mexico. This is being accomplished by Baristas exclusive global distributor agreement with ComNery's Brand Distribution, L.L.C., an Affiliate of Nery's Logistics, the exclusive distributer of Baristas’ line of products across Mexico.
This week, Baristas Coffee Company announced that it has started producing a series of television commercials introducing the public to the Baristas White Coffee single serve cups compatible with the Keurig® 2.0 K-Cup® Brewing System. These commercials will air in support of retail and online sales as the product is launched.
Baristas Coffee Company, Inc. (BCCI), closed Friday's trading session at $0.0175, up 9.38%, on 2,595,549 volume with 7 trades. The average volume for the last 60 days is 14,496,771 and the stock's 52-week low/high is $0.0001/$0.03.
Bio-AMD, Inc. (BIAD)
Today we are reporting on Bio-AMD, Inc. (BIAD), here at the QualityStocks Daily Newsletter.
Cheshire, England-based Bio-AMD, Inc. has two majority owned United Kingdom (UK) subsidiaries. One is Bio-AMD Ltd., which is a technology developer for medical diagnostic devices. The other is WOCU Ltd., the owner of the WOCU®, a global currency data reference source for application in financial markets. The Company has positioned itself as a top innovator in the field of reader technology development.
Bio-AMD is the 63 percent owner of Bio-AMD Ltd., a technology development company positioned in the fast developing Point of Care (PoC) medical diagnostics sector. PoC medical diagnostics is a multi-billion-dollar global market.
Currently, Bio-AMD has three proprietary technology platforms. These technology platforms include a disposable micro-fluidic test strip that has been adapted to measure prothrombin time (PT)/INR through a PoC blood coagulation monitoring device (COAG) enabling patient based, anticoagulant drug therapy monitoring.
Bio-AMD’s platforms also include a Digital Strip Reader (DSR). It can read an extensive array of lateral flow based immunoassay diagnostic test strips already in the PoC market including, but not limited to, cardiac markers, infectious diseases, drugs of abuse, and female wellbeing (pregnancy/ovulation testing) to provide semi-quantitative results.
The DSR technology platform uses a patented, proprietary method for reading and quantifying traditional chromatography based, nitro-cellulose, lateral-flow immunoassay tests, centered on what Bio-AMD believes to be an inventive optical sensor arrangement. The DSR consists of a proprietary design incorporating sensors, diagnostics, and display and power management capabilities.
The Company is also developing a fully quantitative Magnetic Immunoassay Detection System (MIDS). Its expectation is that this will have a substantially enhanced sensitivity based on magnetic nano-particle manipulation and detection, which can interpret results on a quantitative basis. Initially, it plans to develop MIDS for a panel of POC cardiac marker tests, such as troponin (cTnI or cTnT), myoglobin and creatine kinase MB isoenzyme (CK-MB), used to diagnose myocardial infarction (heart attack) and its severity. The Company’s ultimate goal is to commercialize a product for the multiple cardiac marker testing market.
Last month, Bio-AMD announced that it was informed by its patent attorney that a patent application made in the People's Republic of China (PRC) for its Magnetic Immunoassay Detection System (MIDS) technology is to be granted, subject to routine administration matters. The Company stated that a further announcement will be made when the official grant is confirmed by the State Intellectual Property Office of the PRC.
Furthermore, Bio-AMD announced that it will soon complete its patient blood testing and analysis program at the Wythenshawe Hospital, part of the University Hospital of South Manchester NHS Foundation Trust. These results are applicable to Bio-AMD’s development work. In addition, Bio-AMD has entered into preliminary discussions with a potential partner to offer a disposable device for common STD tests linked to voluntary screening provided by the UK National Health Service (NHS).
Bio-AMD, Inc. (BIAD), closed Friday's trading session at $0.0539, down 10.17%, on 346,365 volume with 23 trades. The average volume for the last 60 days is 21,898 and the stock's 52-week low/high is $0.05/$0.30.
Nippon Dragon Resources, Inc. (RCCMF)
OTC Markets Group and Streetwise Reports reported earlier on Nippon Dragon Resources, Inc. (RCCMF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Based in in Brossard, Quebec, Nippon Dragon Resources, Inc. is a hybrid mining & technology company. It has high potential and advanced stage mining assets combined with an innovative and exclusive green mining method. The Company previously went by the name Rocmec Mining, Inc. It changed its name to Nippon Dragon Resources, Inc. in April of 2014.
Nippon Dragon Resources is active in the exploration and development of gold resources in the Province of Quebec. Its flagship gold property is Rocmec 1. This is a fully permitted project in Quebec. The project includes a 100-meter deep, two-compartment shaft, and an 844 meters’ decline, permitting access to four levels (50, 90, 110 and 130 meters). The latest NI 43-101 report states gold resources of 125,000 ounces in measured/indicated, and 360,000 gold ounces of inferred resources.
The Company has its Thermal Fragmentation mining method. This is a mining method that utilizes heat to 'spall' high-grade veins, significantly lessening the use of explosives. The method only extracts the mineralized ore with minimal dilution.
The extraction process permits thermal fragmentation with an accuracy of 2 cm to quickly extract any kind of hard rock up to 110 cm wide. With this precision, high grade precious and base metal veins can now undergo extraction without dilution. The thermal unit can be set up to extract a specific corridor.
The major advantages of the Thermal Fragmentation Mining Method are reduced dilution, substantial cost savings, and complete mechanization. In addition, this method reduces the impact on the environment and extends mine life. Moreover, Resources are converted to Reserves; the method strengthens sustainability and project acceptance; and mining permits are obtained quicker and easier. Additionally, the method contributes to a low cost slot raise and cost effective bulk sampling.
In April 2015, Nippon Dragon Resources announced that it signed an exclusive distribution agreement with SAFESCAPE for its patented Thermal Fragmentation mining method in various contracts and mining operations throughout Australia, New Zealand, Papua New Guinea, Indonesia and the Philippines (the Territory).
Highlights of this distributorship agreement include the granting of the exclusive rights to SAFESCAPE for the usage, distribution, training and marketing of the Method by SAFESCAPE. Of note is that SAFESCAPE will have the exclusivity in the Territory for a period of five years once certain terms specified within the agreement have been met. The intention is that the revenues produced by the agreement be based using a monthly Intellectual Property (IP) fee model and an equipment-leasing model.
Nippon Dragon Resources, Inc. (RCCMF), closed Friday's trading session at $0.0666, up 18.09%, on 49,300 volume with 5 trades. The average volume for the last 60 days is 34,079 and the stock's 52-week low/high is $0.0236/$0.1121.
QuantumSphere, Inc. (QSIM)
Today we are reporting on QuantumSphere, Inc. (QSIM), here at the QualityStocks Daily Newsletter.
QuantumSphere, Inc. is a foremost producer of advanced catalyst technologies. The design of these is to improve production efficiencies in large-scale industrial chemical processes. The Company’s technology is applicable to hundreds of chemical plants around the world, which represent billions of dollars in yearly output. QuantumSphere has its corporate headquarters in Santa Ana, California.
The Company’s products take advantage of a patented process to produce an innovative high surface area catalyst accelerator technology that improves existing catalyst performance. QuantumSphere’s catalyst accelerator technology is integrated into existing chemical plants with no modifications. Its lead chemical focus is ammonia, which is vital to the worldwide food supply. More than 80 percent of ammonia produced is utilized in agricultural fertilizers for worldwide food production.
Pertaining to the Company’s Intellectual Property (IP), it was awarded the patent for its gas phase condensation (GPC) process on October 16, 2007. The patent includes dozens of wide-ranging claims on the manufacturing system that produces advanced materials, high surface area catalysts at the nano scale.
Concerning its process, the Company’s patented process is safe, environmentally friendly, and also fully automated. It requires low supervision and little down time for reactor maintenance. QuantumSphere’s advanced catalysts have top-quality properties. This includes their spherical shape, oxide layer, crystalline structure, as well as very large surface area. This transforms into higher reaction activity and greater efficiency in the generation, storage, and use of energy.
In addition, QuantumSphere has further patent applications pending associated to composition of nano alloys, process chemistries, and commercial devices (high rate electrodes for metal-air batteries and fuel cells) enabled by the use of the Company’s advanced catalyst materials and integrated catalytic solutions.
In November of 2015, QuantumSphere announced that Frost & Sullivan presented QuantumSphere with its 2015 North American Nanocatalysts Technology Innovation Award. The Frost & Sullivan award states that “QuantumSphere’s ability to enhance ammonia production with its FeNIX™ nanocatalyst coating promises commercial growth for the company as ammonia producers adopt this exciting new technology. Frost & Sullivan finds enormous market opportunities for FeNIX across the globe.”
Last week, QuantumSphere announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a key patent application related to its advanced FeNIX™ nanocatalyst accelerator technology. The patent covers claims around the application of iron nanocatalysts, applied as a coating onto existing commercial ammonia catalysts, for increased catalytic activity and production efficiency in ammonia synthesis.
QuantumSphere, Inc. (QSIM), closed Friday's trading session at $0.80, down 11.11%, on 7,200 volume with 6 trades. The average volume for the last 60 days is 2,966 and the stock's 52-week low/high is $0.90/$3.75.
GTX Corp. (GTXO)
The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.009, up 4.65%, on 78,550 volume with 3 trades. The stock’s average daily volume over the past 60 days is 455,020, and its 52-week low/high is $0.0052/$0.023.
GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.
GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.
The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.
As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.
"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer
GTX Corp. Company Blog
GTX Corp. News:
GTX Corp to Present at 2nd Annual Innovations Investor Conference and Announces Date of Shareholder Meeting
GPS SmartSoles Launch in Latin America
GTX Corp Engages Maxim Group LLC to Provide Strategic Advisory Services
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $2.40, up 5.73%, on 2,855 volume with 14 trades. The stock’s average daily volume over the past 60 days is 12,453, and its 52-week low/high is $1.25/$11.625.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.77, up 2.67%, on 56,305 volume with 50 trades. The stock’s average daily volume over the past 60 days is 18,987, and its 52-week low/high is $0.20/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.
Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.
The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.
Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Announces New Corporate Image, Branding and Media Communications Tools as it Enters Full-Scale Production for 2016
Oakridge Providing Batteries for Unmanned Maritime Vessels
Oakridge Sells Interest in Leclanche S.A., Releasing Funding for Corporate Growth
Cherubim Interests, Inc. (CHIT)
The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0001, even for the day, on 44,859,076 volume with 20 trades. The stock’s average daily volume over the past 60 days is 79,408,343, and its 52-week low/high is $0.0001/$0.33.
Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.
The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.
Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.
Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer
Cherubim Interests, Inc. Company Blog
Cherubim Interests, Inc. News:
Cherubim Interests, Inc. Signs MOU to Acquire Revenue-Producing Company
Cherubim Interests Inc. Announces FINRA Approval of Convertible Preferred Stock Dividend
Cherubim Interests, Inc. Further Bolsters Roster
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0174, off by 3.33%, on 1,199,224 volume with 37 trades. The stock’s average daily volume over the past 60 days is 1,133,636 and its 52-week low/high is $0.0035/$0.40.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Signs Financing Agreement With GHS Capital
Dr. Islam Lectures on the RUBICON Design -- The Industry's First Scalable Single Megawatt SOFC System
Dominovas Energy Acquires Independent Power Producer License From the Angolan Ministry of Petroleum
Today's Top 3
Wall Street Mover
The QualityStocks Public Company Sponsor News